All press releases

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million


Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent


Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.


Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.


Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing...


Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences


ALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANY


Alfasigma Group Redeploys CARNITENE® (L-carnitine) Business in the Chinese Market


Alfasigma launches diagnostic drug Lumeblue™ ahead of World Digestive Health on 29 May


Alfasigma inaugurates the new Research and Development center in Pomezia named after its founder Marino Golinelli


×

You’re entering Alfasigma global website

I agree